SY-12321
/ Shouyao Holdings
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 10, 2026
A Phase 1/2 Study of SY-12321 in Patients With ALK-positive Advanced Malignancies
(clinicaltrials.gov)
- P1/2 | N=330 | Recruiting | Sponsor: Shouyao Holdings (Beijing) Co. LTD
New P1/2 trial • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • ALK
1 to 1
Of
1
Go to page
1